By investigating genetic alterations in p53, Ki67, CD117, EGFR, p16, and VEGF, numerous research have sought to improve MPT categorization and prognosis; however, only p53 expression and the Ki67 index have been proven to be significantly linked with DFS and OS [44–46]. Recently, it was found that MED12 is commonly changed in the initial phases of PT [47]. Notably, genetic mutations in FLNA (28%), SETD2 (21%), and KMT2 (9%) were exclusively found in PT, indicating that it is a distinct component from BS. This evidence concerns the gene MED12 and Bloom syndrome.